TScan Therapeutics Inc
TCRX1.790USD
+0.070+4.07%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
101.58MValor de mercado
PerdaP/L TTM
Mais detalhes de TScan Therapeutics Inc Empresa
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Informações da empresa
Código da empresaTCRX
Nome da EmpresaTScan Therapeutics Inc
Data de listagemJul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
Número de funcionários194
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 16
Endereço830 Winter Street
CidadeWALTHAM
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02451
Telefone18573999500
Sitehttps://www.tscan.com
Código da empresaTCRX
Data de listagemJul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2023
FY2022
FY2021
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
2.17M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Lynx1 Capital Advisors LLC
14.97%
BVF Partners L.P.
9.96%
K2 HealthVentures LLC
6.87%
Baker Bros. Advisors LP
5.31%
The Vanguard Group, Inc.
4.10%
Outro
58.80%
Investidores
Investidores
Proporção
Lynx1 Capital Advisors LLC
14.97%
BVF Partners L.P.
9.96%
K2 HealthVentures LLC
6.87%
Baker Bros. Advisors LP
5.31%
The Vanguard Group, Inc.
4.10%
Outro
58.80%
Tipos de investidores
Investidores
Proporção
Investment Advisor
27.58%
Hedge Fund
21.45%
Venture Capital
19.23%
Investment Advisor/Hedge Fund
7.33%
Research Firm
3.61%
Individual Investor
0.39%
Bank and Trust
0.27%
Outro
20.13%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
192
48.33M
92.38%
-952.90K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
2023Q1
72
14.05M
68.89%
-1.92M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Lynx1 Capital Advisors LLC
7.95M
15.19%
+2.59M
+48.32%
May 20, 2025
BVF Partners L.P.
4.89M
9.35%
+1.90M
+63.56%
Mar 31, 2025
K2 HealthVentures LLC
3.60M
6.89%
+2.90M
+414.67%
Dec 31, 2024
Baker Bros. Advisors LP
2.78M
5.32%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.5%
-25.79K
-1.08%
Mar 31, 2025
Propel Bio Management, LLC
2.09M
3.99%
--
--
Mar 31, 2025
Pitango Venture Capital
2.08M
3.98%
+2.08M
--
Dec 31, 2023
BlackRock Financial Management, Inc.
1.84M
3.53%
-21.35K
-1.14%
Mar 31, 2025
Bessemer Venture Partners
1.25M
2.38%
--
--
Mar 31, 2025
Alphabet, Inc.
1.08M
2.06%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
